online prescription solutions
online discount medstore
pills online
buy lorazepam without prescription
xanax for sale
buy xanax without prescription
buy ambien without prescription
ambien for sale
buy modafinil without prescription
buy phentermine without prescription
modafinil for sale
phentermine for sale
lorazepam for sale
buy lexotan without prescription
bromazepam for sale
xenical for sale
buy stilnox without prescription
valium for sale
buy prosom without prescription
buy mefenorex without prescription
buy sildenafil citrate without prescription
buy adipex-p without prescription
librium for sale
buy restoril without prescription
buy halazepam without prescription
cephalexin for sale
buy zoloft without prescription
buy renova without prescription
renova for sale
terbinafine for sale
dalmane for sale
buy lormetazepam without prescription
nobrium for sale
buy klonopin without prescription
priligy dapoxetine for sale
buy prednisone without prescription
buy aleram without prescription
buy flomax without prescription
imovane for sale
adipex-p for sale
buy niravam without prescription
seroquel for sale
carisoprodol for sale
buy deltasone without prescription
buy diazepam without prescription
zopiclone for sale
buy imitrex without prescription
testosterone anadoil for sale
buy provigil without prescription
sonata for sale
nimetazepam for sale
buy temazepam without prescription
buy xenical without prescription
buy famvir without prescription
buy seroquel without prescription
rivotril for sale
acyclovir for sale
loprazolam for sale
buy nimetazepam without prescription
buy prozac without prescription
mogadon for sale
viagra for sale
buy valium without prescription
lamisil for sale
camazepam for sale
zithromax for sale
buy clobazam without prescription
buy diflucan without prescription
modalert for sale
diflucan for sale
buy alertec without prescription
buy zyban without prescription
buy serax without prescription
buy medazepam without prescription
buy imovane without prescription
mefenorex for sale
lormetazepam for sale
prednisone for sale
ativan for sale
buy alprazolam without prescription
buy camazepam without prescription
buy nobrium without prescription
mazindol for sale
buy mazindol without prescription
buy mogadon without prescription
buy terbinafine without prescription
diazepam for sale
buy topamax without prescription
cialis for sale
buy tafil-xanor without prescription
buy librium without prescription
buy zithromax without prescription
retin-a for sale
buy lunesta without prescription
serax for sale
restoril for sale
stilnox for sale
lamotrigine for sale

Using Apportionment to Rein in the Georgia-Pacific Factors

by Eric E. Bensen & Danielle M. White

9 Colum. Sci. & Tech. L. Rev. 1 (2008) (Published February 19, 2008)

Abstract

In a dramatic departure from well-established patent damages law, which would confine a reasonable royalty to a portion of the profit contributed by the infringed patent, current Federal Circuit precedent permits a reasonable royalty on an even relatively insignificant component to exceed not only the profit attributable to that component, but, in some cases, the entire profit on the product. That precedent ignores the history of the reasonable royalty award, which originated as merely a substitute for an “established” or market rate royalty for the patent. Just as the real-life negotiations leading to an established royalty would result in the licensor and licensee splitting the profit attributable to the licensed patent, a reasonable royalty should leave the infringer with a portion of the profit attributable to the patented invention as compensation for its labor, risk, and investment. The Federal Circuit’s precedent also ignores long-standing apportionment principles, which, if properly applied, would not permit a patentee to derive a reasonable royalty from the unpatented features of an infringing product. Unbound as they are from their economic and legal foundations, royalty awards have, not surprisingly, become arbitrary and often punitive. This article argues that to rein in reasonable royalty awards, restore them to their historical role, and ensure that they are consistent with long-standing principles of patent damages law, (i) apportionment should be the threshold question in every reasonable royalty analysis, and (ii) only factors relevant to approximating a fair market price for the patent should be used to determine the “reasonable” royalty. By treating apportionment as a threshold question, courts can ensure that the resulting reasonable royalty award is properly confined to a portion of the profit attributable to the patent. By looking only to factors relevant to approximating a fair market price, as opposed to an individually negotiated price, courts can ensure that reasonable royalties stay true to their original purpose and avoid reliance on the more subjective Georgia-Pacific factors that give experts so much opportunity for obfuscation. While reasonable people will still be able to disagree about the merits of any particular award, following the steps we describe will ensure that reasonable royalty awards are not punitive, but rather, well-grounded in economic and legal reality.

About the Authors

Eric E. Bensen is co-author of Milgrim on Trade Secrets and Milgrim on Licensing and an attorney with Paul, Hastings, Janofsky & Walker LLP in New York, where he focuses his practice on intellectual property litigation, licensing and counseling.

Danielle M. White is an attorney with Paul, Hastings, Janofsky & Walker LLP in New York, where she focuses her practice on intellectual property litigation and counseling.

Important Note

For proper legal citation of this document, please cite to the following URL: http://www.stlr.org/cite.cgi?volume=9&article=1. The URL that currently appears in your browser’s location toolbar is incorrect. For more information on Bluebook citation of internet sources, click here.

View in PDF

blog comments powered by Disqus